Main Menu

Licensing and partnering opportunities

These are some highlighted research projects ready now for partnering or licensing here at The Institute of Cancer Research – although there are opportunities to collaborate with our scientists across the full range of our research.  

Contact the Business and Innovation office

if you'd like to speak to our researchers – or learn about the Innovation Gateway, a new incubator space in Sutton, South London, which offers unique opportunities to collaborate with us.

Opportunity: AI-based multiplex image analysis of pathology slides (SANDI)

We're seeking licensees or collaborators for an AI-based method that could help accelerate research into how different cell types within the tumour microenvironment influence tumour behaviour, prognosis and response to treatment.

Download the brochure

Opportunity: molecular subtyping and predictive test for personalising colorectal cancer

We're seeking a partner to continue the development of a colorectal cancer gene signature as a clinical test for predicting therapy response (e.g. anti-EGFR therapies, including monoclonal antibodies).

Download the brochure

Opportunity: predictive test for personalising breast cancer treatment

We're seeking partners to continue the development of a gene expression signature into a predictive biomarker for predicting prognosis and treatment response for patients with early-stage ER+/HER2+ breast cancer.

Download the brochure

Opportunity: predictive test for personalising treatment of advanced sarcoma

We are seeking partners to continue the development of a gene expression signature for predicting tumour response to the multi-target tyrosine kinase inhibitor pazopanib and support its transition to the clinic.

Download the brochure

Opportunity: CAR-T therapy development for breast cancer and other solid tumours

We are seeking a partner to continue the development of CAR-T technology targeted against transmembrane glycoprotein Endosialin in breast cancer and other solid tumours.

Download the brochure

Opportunity: new drug in ovarian cancer

We are seeking a partner to enable progression of this phase-II-ready compound and companion biomarker diagnostic test through to mid-late stage clinical development.

Download the brochure

Opportunity: image/AI-driven cancer biomarker to measure immune environment

We are seeking a partner to continue the commercial development of AI-TIL: an image-based biomarker that quantifies tumour-infiltrating lymphocyte (TIL) from histopathological samples using proprietary AI technologies.

Download the brochure

Opportunity: cancer vaccines or immunotherapy to tackle drug resistance

We're seeking a partner to collaborate on the development of anti-cancer vaccines and/or immunotherapeutic approaches to help overcome resistance to PARP inhibition or platinum-based chemotherapy

Download the brochure

Opportunity: IL23 inhibitors in prostate cancer

We are seeking a partner to continue the development of IL-23 inhibitors in advanced, castration resistant prostate cancer following the surprising discovery that IL-23 secreted by myeloid suppressor cells confers resistance to androgen deprivation therapy.

Download the brochure

Opportunity: ARID1A and other BAF complex defects as biomarkers for ATRi resistance

We are seeking a partner to continue the development of ARID1A and other BAF-complex genes as cancer biomarkers for predicting sensitivity to ATR inhibitors.

Download the brochure

Opportunity: predicting radiotherapy response in bladder cancer

We are seeking a partner to continue the development of a gene expression profiling method for predicting response to radiotherapy in muscle invasive bladder cancer.

Download the brochure

Opportunity: biomarker for CDK4/6 and/or aromatase inhibitor response in breast cancers

We're seeking a partner to to continue the development of a breast cancer gene signature for predicting resistance/sensitivity to aromatase inhibitors and/or CDK4/6 inhibitors.

Download the brochure